






Memorandum – Immunology #15

To: UNCCMC Attending Physicians, Faculty Practice Physicians,
Housestaff, Clinical Nurse Coordinators, Department Heads, and
Supervisors

From:  John L. Schmitz, Ph.D.
Director, Immunology Laboratory

 Eric T. Weimer, Ph.D.
Associate Director, Immunology Laboratory

 Herbert C. Whinna, M.D., Ph.D.
Medical Director, McLendon Clinical Laboratories

Date: August 9, 2022

Subject: Glomerular Basement Membrane Antibody Testing

Effective 8/15/2022 the Immunology laboratory will perform glomerular basement membrane (GBM) antibody testing in house using the ELiA GBM antibody test on the Phadia 250 platform. This testing will replace the current send-out test to Mayo Medical Laboratories.

The ELiA GBM antibody test is a semi-quantitative assay for detection of IgG antibodies to the $\alpha 3$ chain of collagen IV. The test is an aid in the diagnosis of anti-GBM disease and Goodpasture syndrome. The test is validated for serum only. Samples can be held at room temperature up to 8 hours after collection. Refrigerated samples may be held up to 2 weeks prior to testing.

Results are reported in U/ml and interpreted as follows:

Negative: <7 ELiA U/ml

Equivocal: 7 – 10 ELiA U/ml

Positive: >10 ELiA U/ml

Repeat testing of patients with equivocal results is recommended after 8 to 12 weeks.

Clinical studies performed by the vendor demonstrated a sensitivity of 94.2% for results >10 U/ml (based on 69 patients with Goodpasture syndrome). Specificity was 99.4% (based on 320 disease control subjects).

GBM antibody testing can be ordered in EPIC – Glomerular Basement Membrane Antibodies or LAB727.

Questions regarding this testing can be directed to the Immunology laboratory (984-974-1815).